Affordable Access

Publisher Website

Coronary stenting in cardiac allograft vasculopathy

Journal of the American College of Cardiology
Publication Date
DOI: 10.1016/s0735-1097(98)00432-x
  • Interventional Cardiology
  • Medicine


Abstract Objective. The purpose of this study was to evaluate acute angiographic success, in-hospital complications and long-term outcome after intracoronary stenting in patients with cardiac allograft vasculopathy. Background. The application of conventional interventional modalities to treat discrete lesions in patients with cardiac allograft vasculopathy is associated with higher procedural morbidity, mortality and higher restenosis compared to atherosclerotic coronary artery disease. Elective coronary stenting has been shown to lower restenosis rates and improve long-term outcome in selected patients with native coronary artery disease; however, its safety and efficacy in reducing restenosis in patients with cardiac allograft vasculopathy is unknown. Methods. Ten patients with 19 discrete lesions in a major coronary artery without diffuse distal disease underwent intracoronary stenting using Palmaz–Schatz stents. The average stent size was 3.4 mm, and the stent/artery ratio was 0.99 ± 0.07. Eight of ten (80%) patients received antiplatelet therapy (aspirin plus ticlopidine) only. Results. Procedural success was 100% with no in-hospital stent thrombosis, Q-wave myocardial infarction or death. Minimal luminal diameter increased from 0.83 ± 0.38 mm to 3.23 ± 0.49 mm after stenting. Diameter stenosis decreased from 74.91 ± 11.52% to 5.90 ± 4.09% after stenting. Follow-up angiography was performed in 8 of 10 (80%) patients and 16 of 19 (84%) lesions. Target lesion revascularization was required in 2 of 10 (20%) patients and 3 of 16 (19%) lesions. Allograft survival was 7 of 10 (70%) at the end of 22 ± 11 months follow-up. Conclusions. Intracoronary stenting can be performed safely with excellent angiographic success in selected patients with cardiac allograft vasculopathy. The restenosis rate appears to be low despite the aggressive nature of the disease. A multicenter study with a larger number of patients is required to assess its efficacy in reducing restenosis and improving allograft survival.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times